Skip to main content

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology

Université Paris – Diderot, Sorbonne-Paris Cité

Professor, National Heart and Lung Institute

Imperial College, London, UK

Director, Coronary Care Unit

Hôpital Bichat

Paris, France

Related Videos

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

Since ESC and ACC/AHA are examining hard LDL-C targets for patients at risk for ASCVD, how does ODYSSEY Outcomes help inform cardiologists about the rationale for PCSK9-mediated lowering to achieve ultra-low levels (i.e. <50 mg/dL) of LDL-C?

Since ESC and ACC/AHA are examining hard LDL-C targets for patients at risk for ASCVD, how does ODYSSEY Outcomes help inform cardiologists about the rationale for PCSK9-mediated lowering to achieve ultra-low levels (i.e. <50 mg/dL) of LDL-C?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

What unique aspects, with respect to all-cause mortality outcomes and baseline LDL-C levels, were observed in the ODYSSEY Outcomes Trial and how would you translate these results into patient care?

Can you drill down into the specific results of the ODYSSEY Outcomes Trial that demonstrate unique, significant reductions in associated all-cause mortality and how these findings might be relevant to the interventional cardiologist?

Can you drill down into the specific results of the ODYSSEY Outcomes Trial that demonstrate unique, significant reductions in associated all-cause mortality and how these findings might be relevant to the interventional cardiologist?

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

In a high-risk patient who has undergone multiple stent procedures, what criteria do you prioritize for initiating a PCSK9 inhibitor in the setting of PCI, and what absolute LDL-C targets are in your cross-hairs based on the ODYSSEY Outcomes Trial?

Can you help us de-convolute what is more important, (a) the absolute level of LDL-C level attained among patients in the ODYSSEY Outcomes Trial, or (b) the delta, i.e. the relative change from baseline LDL-C level at time of entry into the trial?

Can you help us de-convolute what is more important, (a) the absolute level of LDL-C level attained among patients in the ODYSSEY Outcomes Trial, or (b) the delta, i.e. the relative change from baseline LDL-C level at time of entry into the trial?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

From the specific vantage point of the interventional cardiologist, based on the results of the ODYSSEY Outcomes Trial, which patients who have undergone PCI do you believe are the best candidates for PCSK9 therapy?

Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

Based on ODYSSEY Outcomes and FOURIER, what are the findings and/or biologic risk features—Lp(a), for example—in patients managed in an interventional cardiology setting that would make you advocate for the use of PCSK9 inhibitors?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?

Interventional cardiologists have a strong incentive to use PCSK9 inhibitors in many high-risk patients, but real world factors such as cost can present barriers to optimizing CV risk prevention. Can you discuss this and its relevance to the IC?